SPECIAL REPORT
MOST SHARED
- We're Not Greece: Italian Prime Minister Monti
- Obama Likely to Call for Cutting Top Corporate Tax Rate
- To Play Senate Cybersecurity Bill, Cramer Likes Fortinet Stock
- Greek Cabinet Approves EU, IMF Bailout Bill
- Special Feature: Wall Street History - How Wall Street Got Its Name
- How to Trade the Turmoil in Greece
- Private Homebuilders: Dead Men Walking
- Why Cramer Likes Select Comfort Over Tempur-pedic Stock
- Cramer: 10 Earnings to Watch Next Week
- Lightning Round: Trina Solar, Zoltek, Affymax and More
- In Search of America's ‘Hottest Forecasters’
- Dow vs. S&P 500: Which is a Better Investment?
- Mick Fleetwood on the MP3 ‘Dumbing Down’ of Music
- Avis on the Road to Strong Growth: Analyst
- Private Homebuilders: Dead Men Walking
- LinkedIn’s Growth Is Already Priced In: Analyst
- The Real Reason Behind Bank of America’s Rally
- 5 Hedge Funds’ Top Stocks Soar After 2011 Rout
- This Valentine’s Day Love Is Served on a Silver Platter
- Greek Cabinet Approves EU, IMF Bailout Bill
- We're Not Greece: Italian Prime Minister Monti
- Private Homebuilders in the US: Dead Men Walking
- Dividend Payout Could Hit Record Amount This Year
- With Investors So Bullish, Stock Pullback Must Be Ahead
- Obama Likely to Call for Cutting Top Corporate Tax Rate
- New York Fashion Week Fall 2012
- NetNet: Why Saving Greece Could Destroy the World
- My Funny Valentine: When Love and the Fed Collide
RSS FEED
Pharma's Market
Text Size 
A Tale Of Two Industries
 |
Getty Images Jamie Dimon |
] Chairman and CEO Jamie Dimon was asked to give his worst-case scenario for the economy. He said that'd be a 1982-type recession lasting about two years and with unemployment "North of 10 percent." Dimon said it would be "Irrational to not be prepared for that." A common refrain in investment circles is that healthcare is recession-proof.
It's less economy-related than it is fundamentals-related, but today comes word out of our partners at "The Wall Street Journal" that Pfizer [PFE
Loading...
()
] is planning to lay off 800 researchers.
But the contrast between the downsizing in big pharma and the picture in the upstart biotech sector can be striking.
This morning while killing time before my live interview with Vertex Pharmaceuticals [VRTX
Loading...
()
] CEO Joshua Boger, he told me that his company took in 11,000 applications last year for 300 positions. "It's tougher than getting into Harvard," said Boger whose company is headquartered in Harvard's home town of Cambridge, MA. And VRTX, which is ramping up for its hepatitis C drug, is still hiring a few people a week.
It's an anecdote. It doesn't mean that biotech is immune from the troubles plaguing the economy, the drug sector and the markets. A lot of money-losing biotechs with no products on the market can't access the capital markets right now. And that's forcing many of them to better conserve what little cash they have on hand. That can mean layoffs and scuttling of earlier stage research and development projects.
The Biotechnology Industry Organization says that's putting innovation at risk and is calling for a federal tax break for baby biotechs that aren't making money. Jamie Dimon doesn't like that idea. In response to a question about it yesterday he said gesturing with one arm and then the other—and I'm paraphrasing a wee bit—"If something stupid happens over here, why would you do something stupid over there?" The audience laughed.
Questions? Comments?
Data is a real-time snapshot *Data is delayed at least 15 minutes
